Sapien Maintains Big Benefit In Inoperable Patients At Two Years

14 Nov 2011

Recent launch of the transcatheter aortic heart valve for patients too sick for open heart surgery may get a lift from data presented at TCT.

Edwards Lifesciences’ recent U.S. launch of its Sapien transcatheter aortic heart valve to treat patients who are not candidates for open heart surgery may get a lift from data presented at the Transcatheter Cardiovascular Therapeutics conference on Nov. 10.

Investigators reported at the San Francisco meeting two-year data from Edwards’ PARTNER/cohort B trial comparing the valve to best medical therapy in inoperable patients, just a week after Edwards announced...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

22 May 2025

• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

21 May 2025

• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

20 May 2025

• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.